LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

10X Genomics Inc (Class A)

Closed

SectorHealthcare

9.4 2.62

Overview

Share price change

24h

Current

Min

8.93

Max

9.4

Key metrics

By Trading Economics

Income

15M

-34M

Sales

-10M

155M

EPS

-0.102

Profit margin

-22.183

Employees

1,306

EBITDA

-1.5M

-39M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+37.72% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

108M

1.2B

Previous open

6.78

Previous close

9.4

News Sentiment

By Acuity

50%

50%

177 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

10X Genomics Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

16 May 2025, 19:39 UTC

Major Market Movers

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 May 2025, 23:18 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 May 2025, 22:30 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- Update

16 May 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 May 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 May 2025, 21:54 UTC

Top News

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 May 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 May 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 May 2025, 21:17 UTC

Top News

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 May 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 May 2025, 20:55 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 May 2025, 20:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

16 May 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 May 2025, 20:37 UTC

Top News

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 May 2025, 20:33 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 May 2025, 20:30 UTC

Acquisitions, Mergers, Takeovers

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 May 2025, 20:18 UTC

Top News

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 May 2025, 20:16 UTC

Top News

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 May 2025, 20:15 UTC

Earnings

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 May 2025, 20:11 UTC

Acquisitions, Mergers, Takeovers

Henry Schein: William K. Daniel Joins Board

16 May 2025, 20:10 UTC

Acquisitions, Mergers, Takeovers

Henry Schein: Strategic Investment by KKR Completed

16 May 2025, 20:05 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 May 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 May 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 May 2025, 18:51 UTC

Top News

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 May 2025, 18:41 UTC

Acquisitions, Mergers, Takeovers

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 May 2025, 18:37 UTC

Market Talk

Gold Futures End Week on Negative Note -- Market Talk

16 May 2025, 18:35 UTC

Top News

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 May 2025, 18:32 UTC

Top News

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 May 2025, 18:28 UTC

Market Talk

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Peer Comparison

Price change

10X Genomics Inc (Class A) Forecast

Price Target

By TipRanks

37.72% upside

12 Months Forecast

Average 12.56 USD  37.72%

High 15 USD

Low 9 USD

Based on 11 Wall Street analysts offering 12 month price targets for10X Genomics Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

4

Buy

7

Hold

0

Sell

Technical Score

By Trading Central

8.32 / 8.63Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

177 / 382 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.